Myelodysplastic Syndromes Clinical Trials & Research Studies Near You (Updated 4/24)

Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

NCT04013685

Recruiting

This study will evaluate the safety, tolerability, and efficacy of Orca-T, an allogeneic stem cell and T-cell immunotherapy biologic manufactured for each patient (transplant recipient) from the mobilized peripheral blood of a specific, unique donor. It is composed of purified hematopoietic stem and progenitor cells (HSPCs), purified regulatory T cells (Tregs), and conventional T cells (Tcons) in participants undergoing myeloablative allogeneic hematopoietic cell transplant transplantation for h... Read More

Gender:

All

Ages:

Between 18 years and 75 years

Trial Updated:

04/08/2024

Locations: City of Hope, Duarte, California +21 locations

Conditions: Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Myelodysplastic Syndromes, Acute Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), Chronic Myeloid Leukemia

Register for Updates

Learn More ›

A Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Participants With International Prognostic Scoring System Revised (IPSS-R) Low- or Intermediate-risk Myelodysplastic Syndrome (MDS)

NCT05469737

Recruiting

The purpose of this study is to evaluate the safety and efficacy of oral azacitidine in participants with low to intermediate International Prognostic Scoring System Revised (IPSS-R) myelodysplastic syndrome (MDS).

Gender:

All

Ages:

18 years and above

Trial Updated:

04/08/2024

Locations: University of Miami Hospital and Clinics, Sylvester Cancer Center, Miami, Florida +127 locations

University of Miami Hospital and Clinics, Sylvester Cancer Center, Miami, Florida

Advanced Research, Tamarac, Florida

Local Institution - 0095, Tampa, Florida

Local Institution - 0173, Louisville, Kentucky

Local Institution - 0174, Detroit, Michigan

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey

Hematology-Oncology Associates of Central New York, PC, East Syracuse, New York

Memorial Sloan Kettering Cancer Center, New York, New York

Novant Health Presbyterian Medical Center, Charlotte, North Carolina

Local Institution - 0096, Portland, Oregon

AHN West Penn Hospital, Pittsburgh, Pennsylvania

Charleston Oncology, P.A., Charleston, South Carolina

Houston Methodist Hospital, Houston, Texas

University of Texas MD Anderson Cancer Center, Houston, Texas

Huntsman Cancer Institute, Salt Lake City, Utah

Inova Schar Cancer Institute, Fairfax, Virginia

Local Institution - 0070, Pilar, Buenos Aires

Local Institution - 0039, ABB, Ciudad Autónoma De Buenos Aires

Local Institution - 0021, Buenos Aires, Ciudad Autónoma De Buenos Aires

Centro Mdico "Barrio Parque", Buenos Aires, Not set

Local Institution - 0022, Buenos Aires, Not set

Local Institution - 0050, Buenos Aires, Not set

Local Institution - 0144, Darlinghurst, New South Wales

Local Institution - 0145, Macquarie University, New South Wales

Local Institution - 0146, Wollongong, New South Wales

Local Institution - 0006, Clayton, Victoria

Local Institution - 0069, Heidelberg, Victoria

Local Institution - 0018, Melbourne, Victoria

Local Institution - 0004, Melbourne, Victoria

Local Institution - 0003, Melbourne, Not set

Local Institution - 0034, Linz, Oberösterreich

Local Institution - 0029, Vienna, Wien

Local Institution - 0074, Salzburg, Not set

Local Institution - 0091, Calgary, Alberta

Local Institution - 0008, Toronto, Ontario

Local Institution - 0015, Toronto, Ontario

Local Institution - 0090, Montréal, Quebec

Local Institution - 0171, Beijing, Beijing

Local Institution - 0167, Guangzhou, Guangdong

Local Institution - 0157, Wuhan, Hubei

Local Institution - 0156, Wuhan, Hubei

Local Institution - 0168, Changsha, Hunan

Local Institution - 0162, Nanjing, Jiangsu

Local Institution - 0163, Suzhou, Jiangsu

Local Institution - 0179, Changchun, Jilin

Local Institution - 0166, Shenyang, Liaoning

Local Institution - 0160, Xian, Shaanxi

Local Institution - 0169, Jinan, Shandong

Local Institution - 0164, Qingdao, Shandong

Local Institution - 0165, Taiyuan, Shanxi

Local Institution - 0141, Hangzhou, Zhejiang

Local Institution - 0161, Ningbo, Zhejiang

Local Institution - 0170, Zhengzhou, Not set

Local Institution - 0009, Brno, Brno-město

Local Institution - 0060, Hradec Kralove, Not set

Local Institution - 0045, Praha 2, Not set

Local Institution - 0115, Aarhus, Midtjylland

Local Institution - 0116, Aalborg, Nordjylland

Local Institution - 0114, Odense, Syddanmark

Local Institution - 0025, Nice, Alpes-Maritimes

Local Institution - 0063, Pessac, Aquitaine

Local Institution - 0024, Tours, Indre-et-Loire

Local Institution - 0094, Angers, Maine-et-Loire

Local Institution - 0056, Lille, Nord

Local Institution - 0085, Villejuif, Val-de-Marne

Local Institution - 0082, Paris, Not set

Local Institution - 0076, Kempten, Bayern

Local Institution - 0059, Munich, Bayern

Local Institution - 0081, Duisburg, Nordrhein-Westfalen

Local Institution - 0128, Düsseldorf, Nordrhein-Westfalen

Local Institution - 0055, Leipzig, Sachsen

Local Institution - 0037, Dresden, Not set

Local Institution - 0007, Hamburg, Not set

Local Institution - 0028, Mutlangen, Not set

Attikon General University Hospital, Chaidari, Attikí

Local Institution - 0129, Thessaloniki, Thessaloníki

Local Institution - 0127, Alexandroupolis, Not set

Local Institution - 0178, Hksar, Not set

Local Institution - 0180, Shatin, Not set

Fondazione Policlinico Tor Vergata, Rome, Lazio

Local Institution - 0088, Milano, Lombardia

Local Institution - 0052, Rozzano, Milano

Local Institution - 0075, Firenze, Toscana

Local Institution - 0089, Padova, Veneto

IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico di Sant'Orsola, Bologna, Not set

Local Institution - 0067, Pavia, Not set

Local Institution - 0053, Reggio Calabria, Not set

Local Institution - 0143, Roma, Not set

Local Institution - 0183, Matsuyama, Ehime

Japan Community Healthcare Organization Kyushu Hospital, Kitakyushu-shi, Fukuoka

Local Institution - 0187, Kitakyushu, Fukuoka

Local Institution - 0182, Ogaki, Gifu

Local Institution - 0186, Maebashi, Gunma

Local Institution - 0185, Fukuyama, Hiroshima

Aiiku Hospital, Sapporo, Hokkaido

Local Institution - 0153, Amagasaki, Hyogo

Local Institution - 0184, Higashiibaraki, Ibaraki

Local Institution - 0188, Hitachi, Ibaraki

Local Institution - 0130, Sagamihara, Kanagawa

Local Institution - 0135, Sendai-shi, Miyagi

Local Institution - 0181, Itabashiku, Tokyo

Local Institution - 0150, Shinagawa-ku, Tokyo

Osaka Metropolitan University Hospital, Osaka, Not set

Local Institution - 0058, Hwasun Gun, Jeonranamdo

Local Institution - 0048, Seoul, Seoul Teugbyeolsi

Local Institution - 0036, Seoul, Seoul-teukbyeolsi [Seoul]

Local Institution - 0012, Seoul, Seoul-teukbyeolsi [Seoul]

Local Institution - 0051, Jung-gu, Taegu-Kwangyǒkshi

Local Institution - 0044, Wroclaw, Dolnośląskie

Local Institution - 0097, Olsztyn, Warmińsko-mazurskie

Local Institution - 0043, Katowice, Not set

Local Institution - 0105, Barcelona, Barcelona [Barcelona]

Local Institution - 0106, L'Hospitalet de Llobregat, Catalunya [Cataluña]

Local Institution - 0109, Valencia, Valenciana, Comunitat

Local Institution - 0107, Granada, Not set

Local Institution - 0111, Madrid, Not set

Local Institution - 0112, Orense, Not set

Local Institution - 0110, Oviedo, Not set

Local Institution - 0108, Salamanca, Not set

Local Institution - 0117, Lund, Skåne Län [se-12]

Local Institution - 0118, Stockholm, Stockholms Län [se-01]

Local Institution - 0113, Gothenburg, Västra Götalands Län [se-14]

Local Institution - 0119, Örebro, Örebro Län [se-18]

Local Institution - 0077, st.Gallen, Sankt Gallen

Local Institution - 0066, Basel, Not set

Local Institution - 0139, Pendik, İstanbul

Local Institution - 0138, İzmir, Not set

Local Institution - 0140, Samsun, Not set

Conditions: Myelodysplastic Syndromes

Register for Updates

Learn More ›

Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA

NCT04798339

Recruiting

This study is a multi-institution, open-label, Phase 1b/2 clinical trial evaluating the toxicity and efficacy of canakinumab in combination with darbepoetin alfa in patients with lower-risk MDS who have failed prior treatment with an Erythropoietin Stimulating Agent (ESA)

Gender:

All

Ages:

18 years and above

Trial Updated:

04/05/2024

Locations: Moffitt Cancer Center, Tampa, Florida +1 locations

Conditions: Myelodysplastic Syndromes

Register for Updates

Learn More ›

Investigation of the Genetics of Hematologic Diseases

NCT02720679

Recruiting

The purpose of this study is to collect and store samples and health information for current and future research to learn more about the causes and treatment of blood diseases. This is not a therapeutic or diagnostic protocol for clinical purposes. Blood, bone marrow, hair follicles, nail clippings, urine, saliva and buccal swabs, left over tissue, as well as health information will be used to study and learn about blood diseases by using genetic and/or genomic research. In general, genetic rese... Read More

The purpose of this study is to collect and store samples and health information for current and future research to learn more about the causes and treatment of blood diseases. This is not a therapeutic or diagnostic protocol for clinical purposes. Blood, bone marrow, hair follicles, nail clippings, urine, saliva and buccal swabs, left over tissue, as well as health information will be used to study and learn about blood diseases by using genetic and/or genomic research. In general, genetic research studies specific genes of an individual; genomic research studies the complete genetic makeup of an individual. It is not known why many people have blood diseases, because not all genes causing these diseases have been found. It is also not known why some people with the same disease are sicker than others, but this may be related to their genes. By studying the genomes in individuals with blood diseases and their family members, the investigators hope to learn more about how diseases develop and respond to treatment which may provide new and better ways to diagnose and treat blood diseases. Primary Objective: Establish a repository of DNA and cryopreserved blood cells with linked clinical information from individuals with non-malignant blood diseases and biologically-related family members, in conjunction with the existing St. Jude biorepository, to conduct genomic and functional studies to facilitate secondary objectives. Secondary Objectives: Utilize next generation genomic sequencing technologies to Identify novel genetic alternations that associate with disease status in individuals with unexplained non-malignant blood diseases. Use genomic approaches to identify modifier genes in individuals with defined monogenic non-malignant blood diseases. Use genomic approaches to identify genetic variants associated with treatment outcomes and toxicities for individuals with non-malignant blood disease. Use single cell genomics, transcriptomics, proteomics and metabolomics to investigate biomarkers for disease progression, sickle cell disease (SCD) pain events and the long-term cellular and molecular effects of hydroxyurea therapy. Using longitudinal assessment of clinical and genetic, study the long-term outcomes and evolving genetic changes in non-malignant blood diseases. Exploratory Objectives Determine whether analysis of select patient-derived bone marrow hematopoietic progenitor/stem (HSPC) cells or induced pluripotent stem (iPS) cells can recapitulate genotype-phenotype relationships and provide insight into disease mechanisms. Determine whether analysis of circulating mature blood cells and their progenitors from selected patients with suspected or proven genetic hematological disorders can recapitulate genotype-phenotype relationships and provide insight into disease mechanisms. Read Less

Gender:

All

Ages:

All

Trial Updated:

04/04/2024

Locations: St. Jude Children's Research Hospital, Memphis, Tennessee

Conditions: Bone Marrow Failure Syndromes, Erythrocyte Disorder, Leukocyte Disorder, Hemostasis, Blood Coagulation Disorder, Sickle Cell Disease, Dyskeratosis Congenita, Diamond-Blackfan Anemia, Congenital Thrombocytopenia, Severe Congenital Neutropenia, Fanconi Anemia, Myelodysplastic Syndromes, Myeloproliferative Diseases

Register for Updates

Learn More ›

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

NCT02074839

Recruiting

The purpose of this Phase I, multicenter study is to evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of AG-120 in advanced hematologic malignancies that harbor an IDH1 mutation. The first portion of the study is a dose escalation phase where cohorts of patients will receive ascending oral doses of AG-120 to determine maximum tolerated dose (MTD) and/or the recommended Phase II dose. The second portion of the study is a dose expansion phase where four cohorts of pati... Read More

Gender:

All

Ages:

18 years and above

Trial Updated:

04/03/2024

Locations: University of Alabama at Birmingham, Birmingham, Alabama +28 locations

University of Alabama at Birmingham, Birmingham, Alabama

Mayo Clinic-AZ, Phoenix, Arizona

City of Hope, Duarte, California

University of California-Los Angeles, Los Angeles, California

University of California-San Francisco, San Francisco, California

University of Colorado Denver, Aurora, Colorado

Mayo Clinic-Jacksonville, Jacksonville, Florida

University of Miami, Miami, Florida

Emory University, Atlanta, Georgia

Northwestern University Medical Hospital, Chicago, Illinois

John Hopkins Cancer Center, Baltimore, Maryland

Massachusetts General Hospital, Boston, Massachusetts

Dana Farber Cancer Institute, Boston, Massachusetts

Karmanos Cancer Center, Detroit, Michigan

Washington University, Saint Louis, Missouri

Memorial Sloan Kettering Cancer Center, New York, New York

Cornell Cancer Center, New York, New York

Duke Cancer Center, Durham, North Carolina

Cleveland Clinic, Cleveland, Ohio

Ohio State University, Columbus, Ohio

Oregon Health and Science University, Portland, Oregon

Medical University of South Carolina, Charleston, South Carolina

Sarah Cannon Research Institute, Nashville, Tennessee

UT Southwestern Medical Center, Dallas, Texas

MD Anderson Cancer Center, Houston, Texas

Hopital La Timone, Marseille, Not set

Hopital Haut-Leveque, Pessac, Not set

Central Lyon Sud, Pierre-Bénite, Not set

Institute Gustave Roussly (IGR), Villejuif, Not set

Conditions: Relapsed or Refractory Acute Myeloid Leukemia (AML), Untreated AML, Other IDH1-mutated Positive Hematologic Malignancies, Myelodysplastic Syndromes

Register for Updates

Learn More ›

Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS

NCT04849910

Recruiting

This is a Phase 1/2a, multicenter, open-label, first-in-human (FIH) study of VOR33 in participants with AML or MDS who are undergoing human leukocyte antigen (HLA)-matched allogeneic hematopoietic cell transplant (HCT).

Gender:

All

Ages:

Between 18 years and 70 years

Trial Updated:

04/02/2024

Locations: University of California San Diego Moores Cancer Center, La Jolla, California +9 locations

Conditions: Leukemia, Myeloid, Acute, Myelodysplastic Syndromes

Register for Updates

Learn More ›

Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation

NCT03842696

Recruiting

The purpose of this study is to determine the recommended phase 2 dose of the drug Vorinostat in children, adolescents and young adults following allogeneic blood or marrow transplant (BMT) and determine whether the addition of Vorinostat to the standard graft versus host disease (GVHD) prophylaxis will reduce the incidence of GVHD.

Gender:

All

Ages:

Between 3 years and 39 years

Trial Updated:

04/01/2024

Locations: University of Colorado, Aurora, Colorado +5 locations

Conditions: Hematologic Diseases, Chronic Myelogenous Leukemia - Chronic Phase, Chronic Myelogenous Leukemia, Accelerated Phase, Chronic Myelogenous Leukemia, Blastic Phase, Myelodysplastic Syndromes, Mantle Cell Lymphoma, Follicular Lymphoma, Diffuse Large B Cell Lymphoma, Non Hodgkin Lymphoma, Graft Vs Host Disease, Graft-versus-host-disease, Acute Leukemia in Remission

Register for Updates

Learn More ›

A Phase 1 Study of Engineered Donor Grafts (Orca-Q) in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

NCT03802695

Recruiting

This study will evaluate the safety, tolerability, and efficacy of engineered donor grafts ("OrcaGraft"/"Orca-Q") in participants undergoing myeloablative allogeneic hematopoietic cell transplant transplantation for hematologic malignancies.

Gender:

All

Ages:

Between 18 years and 65 years

Trial Updated:

03/28/2024

Locations: City of Hope, Duarte, California +7 locations

Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Mixed Phenotype Acute Leukemia, Myelofibrosis, Chronic Myeloid Leukemia

Register for Updates

Learn More ›

Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes

NCT04951778

Recruiting

Study CC-91633-AML-001 is a Phase 1, open-label, dose escalation and expansion, first-in-human (FIH) clinical study of CC-91633 (BMS-986397) in participants with relapsed or refractory acute myeloid leukemia (R/R AML) or in participants with relapsed or refractory higher-risk myelodysplastic syndromes (R/R HR-MDS). The Dose Escalation part (Part A) of the study will enroll participants with R/R AML and R/R HR-MDS and will evaluate the safety and tolerability of escalating doses of CC-91633 (BMS-... Read More

Gender:

All

Ages:

18 years and above

Trial Updated:

03/26/2024

Locations: Local Institution - 111, Gilbert, Arizona +28 locations

Local Institution - 111, Gilbert, Arizona

Local Institution - 103, La Jolla, California

Northwestern University School Of Medicine, Chicago, Illinois

Local Institution - 110, Chicago, Illinois

Massachusetts General Hospital, Boston, Massachusetts

Dana Farber Cancer Institute, Boston, Massachusetts

Washington Univ School of Medicine Siteman Cancer Center, Saint Louis, Missouri

Local Institution - 102, Columbus, Ohio

Local Institution - 108, Philadelphia, Pennsylvania

The University of Texas - MD Anderson Cancer Center, Houston, Texas

Local Institution - 109, Seattle, Washington

Local Institution - 604, Adelaide, South Australia

Royal Adelaide Hospital, Adelaide, South Australia

Monash Health, Clayton, Victoria

The Alfred Hospital, Melbourne, Victoria

Local Institution - 603, Melbourne, Victoria

St Vincent's Hospital, Melbourne, Victoria

Local Institution - 203, Vancouver, British Columbia

Local Institution - 201, Ottawa, Ontario

Local Institution - 202, Toronto, Ontario

Vall d Hebron University Hospital, Barcelona, Not set

Hospital Clinic de Barcelona, Barcelona, Not set

Local Institution - 303, Madrid, Not set

Hospital Universitario Virgen del Rocio, Sevilla, Not set

Local Institution - 504, Manchester, Greater Manchester

Local Institution - 502, London, London, City Of

Local Institution - 503, Leeds, Not set

Local Institution - 505, London, Not set

Local Institution - 501, Oxford, Not set

Conditions: Leukemia, Myeloid, Acute, Myelodysplastic Syndromes

Register for Updates

Learn More ›

Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects With MDS or AML

NCT05275439

Recruiting

SL03-Old Hundred(OHD)-104 is designed as a Phase 1a/1b open label, trial to evaluate the safety, pharmacokinetics (PK), pharmacodynamic (PD), and preliminary efficacy of SL-172154 monotherapy as well as in combination with azacitidine or in combination with Azacitidine and Venetoclax.

Gender:

All

Ages:

18 years and above

Trial Updated:

03/21/2024

Locations: City of Hope, Duarte, California +23 locations

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes

Register for Updates

Learn More ›

Acquired Pyruvate Kinase Deficiency In Clonal Myeloid Neoplasms

NCT04902833

Recruiting

This cross-sectional prevalence assessment study involves a single blood draw in specific patient populations to assess for enzymatic and genomic evidence for acquired pyruvate kinase deficiency.

Gender:

All

Ages:

18 years and above

Trial Updated:

03/12/2024

Locations: Massachusetts General Hospital, Boston, Massachusetts

Conditions: Pyruvate Kinase Deficiency, Pyruvate Kinase Deficiency Anemia, Hereditary Hemolytic Anemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasm, Clonal Myeloid Neoplasm, Myeloproliferative Neoplasm, Acute Myeloid Leukemia, Clonal Cytopenia of Undetermined Significance, Other Clonal Myeloid Neoplasm, Unexplained Coombs-negative Non-immune Hemolytic Anemia

Register for Updates

Learn More ›

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

NCT03452774

Recruiting

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention.

Gender:

All

Ages:

All

Trial Updated:

03/12/2024

Locations: Massive Bio, Inc, New York, New York

Conditions: Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver, Cancer of Stomach, Cancer Liver, Cancer of Rectum, Cancer of Kidney, Cancer of Esophagus, Cancer of Cervix, Cancer of Colon, Cancer of Larynx, Cancer, Lung, Cancer, Breast, Cancer, Advanced, Cancer Prostate, Cancer of Neck, Cancer of Skin, Neuroendocrine Tumors, Carcinoma, Mismatch Repair Deficiency, BRCA Gene Rearrangement, Non Hodgkin Lymphoma, Leukemia, Non Small Cell Lung Cancer, Cholangiocarcinoma, Glioblastoma, Central Nervous System Tumor, Melanoma, Urothelial Carcinoma, Bladder Cancer, Ovarian Cancer, Endometrial Cancer, Testicular Cancer, Breast Cancer, COVID, Myelofibrosis, Myeloproliferative Neoplasm, Myeloproliferative Disorders, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Myelodysplastic Syndromes

Register for Updates

Learn More ›

Myelodysplastic Syndromes Clinical Trials

Match to Clinical Trials